Share:
Senate Co-Sponsorship Memoranda
Senate of Pennsylvania
Session of 2017 - 2018
Regular Session
MEMORANDUM
| Posted: | October 2, 2017 08:46 AM |
|---|---|
| From: | Senator Bob Mensch |
| To: | All Senate members |
| Subject: | Recognizing October 13, 2017 as “Metastatic Breast Cancer Awareness Day” in Pennsylvania |
In the near future, I plan to introduce a resolution recognizing October 13, 2017 as “Metastatic Breast Cancer Awareness Day” in Pennsylvania. Metastatic breast cancer, also called stage IV or advanced breast cancer, is not a specific type of breast cancer, but rather the most advanced stage of breast cancer. Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body (most often the bones, lungs, liver or brain). Much of the talk around breast cancer focuses on early detection and routine diagnosis, where we have seen tremendous progress in the last 30 years; however, the story for advanced disease is quite different. Metastatic breast cancer patients continue to face many unique challenges, such as the emotional and physical demands of continual treatment. Currently no cure exists for metastatic breast cancer and those with metastatic breast cancer will continue treatment indefinitely with the goal of extending the best quality life possible. More than one in eight women in the U.S. will be diagnosed with invasive breast cancer in their lifetimes. Specifically in Pennsylvania, it is expected that 11, 300 women will be diagnosed with breast cancer in 2017. Metastatic breast cancer cuts short the lives of too many people in Pennsylvania leaving a lasting effect on their families. It is important that we recognize the need for an additional focus on the personal and social burdens of metastatic breast cancer, the needs of the patient, and promising research efforts in the development of more effective treatments. I ask that you join me in co-sponsoring this resolution to raise awareness and show your support for our family members, neighbors, friends and colleagues affected by metastatic breast cancer. |
Introduced as SR213